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ABSTRACT
Introduction Receiving Bacille Calmette- Guérin (BCG)- 
Denmark vaccine at birth has been associated with ~40% 
reductions in all- cause neonatal mortality. We evaluated 
determinants of BCG skin reaction characteristics by age 2 
months and tested the association with subsequent mortality.
Methods Prospective observational study amalgamating five 
trials providing BCG- at- birth that were conducted between 
2002 and 2018 in Guinea- Bissau. The reaction status and size 
were evaluated at home- visits by 2 months of age among 
6012 neonates; mortality from 2 to 12 months was assessed 
at subsequent visits. Reaction determinants were evaluated by 
binomial regression providing risk ratios (RRs). In Cox- models 
providing adjusted mortality rate ratios (aMRRs), we assessed 
the association between (1) having a 2- month reaction (yes/no) 
and (2) reaction size tertiles and subsequent all- cause mortality 
risk. A subgroup had their BCG reaction evaluated and were 
bled at age 4 weeks; their samples underwent in vitro analysis 
for specific and non- specific cytokine responses.
Results The BCG strain was the main determinant for 
developing a 2- month reaction and the reaction size: the 
BCG- Russia/BCG- Denmark RR for large- reaction was 0.38 
(0.30–0.47) and the BCG- Russia/BCG- Japan RR was 0.61 
(0.51–0.72). 5804 infants (96.5%) were reactors by age 2 
months; 208 (3.5%) were non- reactors. The 2–12 months 
mortality risk was 4.8% (10/208) for non- reactors, 2.9% 
(64/2213) for small reactors, 1.8% (30/1710) for medium 
reactors and 0.8% (15/1881) for large reactors. The reactor/
non- reactor aMRR was 0.49 (0.26–0.95) and there was a linear 
trend of decreasing mortality with increasing reaction size (p for 
trend <0.001). BCG reactors had higher 4- week specific and 
non- specific cytokine responses, responses that were highest 
among those with large reactions.
Conclusion Among BCG- vaccinated infants, having a BCG 
skin reaction by age 2 months was associated with markedly 
better survival, as was the reaction size. Our findings thus 
support that BCG has substantial effects on all- cause mortality. 
Emphasising at- birth vaccination with immunogenic BCG 
strains and revaccinating non- reactors and small reactors could 
have major public health benefits.
Trial registration numbers NCT00146302, 
NCT00168610, NCT00625482, NCT01989026 and 
NCT02447536.
INTRODUCTION
More than 120 million vaccine doses of Bacille 
Calmette- Guérin (BCG) against tuberculosis 
(TB) are administered every year, making 
Key questions
What is already known?
 ► Vaccination with early- Bacille Calmette- Guérin (BCG)- 
Denmark versus no- BCG has been associated with re-
duced neonatal mortality in randomised controlled trials.
 ► The BCG strain and the expertise of the vaccinator 
are the most important determinants for developing 
a BCG scar.
 ► Developing a BCG scar after BCG vaccination during 
infancy is associated with lower subsequent all- cause 
mortality.
What are the new findings?
 ► Among neonates that were BCG- vaccinated early (with-
in 1 week after birth), developing a BCG reaction by 2 
months of age was associated with substantially re-
duced mortality.
 ► The larger the size of the local BCG skin reaction by 2 
months of age, the lower the subsequent mortality.
 ► Compared with BCG- Russia, the BCG- Denmark and 
BCG- Japan strains were associated with a higher inci-
dence of BCG skin reactions and larger skin reactions by 
2 months of age.
What do the new findings imply?
 ► BCG should be given at birth or as soon as possible after 
birth to ensure the development of early BCG reactions, 
and the vaccine should be administered by skilled vacci-
nators to ensure that large reactions develop.
 ► Certain immunogenic BCG strains that contain more vi-
able mycobacteria are likely to induce more beneficial 
non- specific effects.
 ► Vaccination programmes should actively monitor BCG 
skin reaction kinetics among BCG- vaccinated infants, 
since many lives could be saved by increasing the focus 
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BCG one of the world’s most widely used vaccines.1 
BCG vaccination has been associated with beneficial 
effects on all- cause mortality which are not explained 
by protection against TB.2–5 The recommended policy is 
vaccination at birth, but in practice vaccination is often 
delayed. Furthermore, a range of genetically divergent 
BCG strains are used interchangeably. In randomised 
controlled trials (RCTs) conducted in Guinea- Bissau 
among low- weight neonates, receiving BCG- Denmark at 
birth rather than the usual practice of delayed BCG was 
associated with a 38% (95% Confidence Interval (CI): 
17% to 54%) reduction in neonatal mortality and BCG- 
Denmark reduced the risk of fatal sepsis among hospi-
talised neonates by 54% (2% to 78%).3 4 These marked 
beneficial effects could not be ascribed to prevention of 
TB. Hence, as other live vaccines, BCG appears to have 
beneficial non- specific effects (NSEs) inducing resistance 
towards unrelated infections.5 Epigenetic modifications 
of innate immune cells, known as trained innate immunity, 
has been suggested as an immunological pathway.6
Interestingly, observational studies indicate that among 
BCG- vaccinated infants, developing a BCG scar at the 
vaccine injection site is associated with a marked reduc-
tion in all- cause infant mortality.7–13 The main determi-
nants for development of a BCG scar are vaccination 
technique and the BCG strain used.14–16 A small RCT 
from Australia has reported that the BCG- Denmark and 
BCG- Japan strains are associated with higher frequencies 
of mycobacteria- specific T cells, elevated Th1 cytokine 
secretion and larger skin reactions, when compared with 
BCG- Russia.17 Similarly, a recent large- scale RCT from 
Guinea- Bissau reported that BCG- Denmark and BCG- 
Japan are associated with a higher BCG scar prevalence 
and larger scars when compared with BCG- Russia.15
It is unknown whether early BCG skin reactions and 
the size of these reactions affects mortality risk. We there-
fore extracted data from five RCTs conducted in Guinea- 
Bissau where BCG was provided shortly after birth. 
Among infants that had received BCG during the first 
week of life, we reviewed determinants for developing an 
early BCG reaction by 2 months of age and the reaction 
size and evaluated the association with the subsequent 
2–12 month all- cause mortality risk.
METHODS
Setting
The Bandim Health Project (BHP, www. bandim. org) 
maintains a Health and Demographic Surveillance 
System (HDSS) covering approximately 100 000 inhab-
itants in Bissau, the capital of Guinea- Bissau, a devel-
oping country with high infant mortality. The Hospital 
Nacional Simão Mendes (HNSM) is the country’s main 
hospital facility and principal birthplace with 6000–7000 
deliveries/year; it is located within a few kilometres from 
the Bandim HDSS. Since 2002, BHP has conducted a 
series of trials at HNSM evaluating the overall health 
effects of neonatal BCG vaccination.3 15 18–20 At HNSM, 
BHP staff document all births and vaccinations with 
BCG and oral polio vaccine (OPV), which are exclusively 
provided by two experienced BHP vaccinators. In RCT 
V, the post- vaccination weal size was measured to docu-
ment the quality of the vaccination provided. Subsequent 
infant vaccines are provided at smaller health centres in 
accordance with the WHO- recommended immunisation 
schedule.
Patient involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were 
not invited to contribute to the writing or editing of this 
document for readability or accuracy.
Participants
The eligibility criteria for infants to be included in the 
present observational study were: first, to have been 
enrolled in one of five BCG RCTs and have been BCG- 
vaccinated by our team at either HNSM or a HDSS 
health centre during the first week of life (to allow time 
for a skin reaction to have developed at the BCG injec-
tion site by the visit at 2 months of age) and, second, to 
have received standardised home- visits as part of routine 
RCT procedures providing 2- month BCG skin reaction 
data. Mortality data up to 12 months of age was obtained 
through subsequent home- visits (table 1).
Study design: the five BCG RCTs
The five trials had the following study designs: RCT I,18 
RCT II19 and RCT III3 shared the same study design, 
randomising healthy low- weight neonates to early 
BCG- Denmark versus delayed BCG. Only neonates 
randomised to early BCG and thus vaccinated by our 
team were included in the present study. RCT IV20 evalu-
ated the effects of BCG on in- hospital nursery mortality, 
randomising neonates to receive immediate BCG upon 
nursery admission versus BCG at discharge. RCT V15 
randomised neonates to different BCG vaccine strains; 
only the subgroup of infants that resided within the 
HDSS received home follow- up visits and were eligible 
for the present study. Both RCT IV and V were affected 
by a production halt at the BCG- Denmark manufacturer 
occurring in 2015, which lead to the substitution of BCG- 
Denmark with BCG- Japan from July 2016 (table 1).
In all five RCTs, BHP staff vaccinated neonates by intra-
dermal injection of 0.05 mL BCG in the left deltoid region, 
followed by oral administration of OPV. Following intra-
dermal injection of BCG, a superficial post- vaccination 
weal remains visible on the skin for up to 30 min.21 In 
RCT V, our two vaccinators assessed the size of the post- 
vaccination weal immediately after vaccination. Between 
2 and 4 weeks after vaccination, most infants develop a 
papule at the skin site where BCG was injected, and the 
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before healing within 2–5 months leaving a permanent 
superficial scar.22
All RCTs had as exclusion criteria severe malformation 
and being moribund. Infants from families that refused 
our follow- up visits were excluded from analysis. The 
trials were conducted consecutively spanning the years 
2002–2018, during which there was a country- wide trend 
of declining infant mortality.23
Follow-up procedures
BHP field assistants conducted standardised home- visits 
at 2, 6 and 12 months of age (RCTs I–IV) or at 2 and 6 
months of age (RCT V). For RCT V, the 6–12 months 
mortality risk was obtained from the routine HDSS data 
collection. The HDSS provided address information 
used to locate HDSS infants, while BHP staff transported 
non- HDSS infants to their home after enrolment (RCTs 
I–IV); a map was drawn to ensure that the house could 
be located again. At the home- visits, the team collected 
anthropometric data including infant mid upper- arm 
circumference (MUAC) and weight, and assessed 
mortality, morbidity, and adverse events.
The assistant reviewed the infant’s BCG skin reaction 
status by noting the presence or absence of a reaction 
(defined as a BCG papule, pustule or scar) at the vaccine 
injection site on the left upper deltoid and measured 
the horizontal and vertical reaction diameter using a 
transparent ruler (figure 1). Families are often absent 
or travelling; we therefore returned three times to each 
house and, if all visits were unsuccessful, information on 
survival was collected from those present. Infants whose 
family had moved were censored in the survival analysis 
from the date the family had moved.
Immunological subgroup study
As part of the RCT III trial procedures, a subgroup of 
infants was visited at home at 4 weeks of age and bled 
in order to compare BCG group versus control group 
immune responses, when few control group neonates 
had received BCG. Provided that informed consent was 
obtained, their BCG reaction was assessed and a capillary 
blood sample was collected for immunological assess-
ment.24 A whole- blood differential count was performed 
on the EDTA- treated blood on an ABX Pentra60 (Horiba, 
France). In vitro stimulation with PMA and ionomycin, 
purified protein derivative (PPD) from Mycobacte-
rium tuberculosis and different Toll- like receptor (TLR) 
agonists was performed on fresh heparinised blood, 
diluted 1:9 with RPMI-1640 and stimulated for 24 hours 
after which supernatants were harvested. Samples were 
stored and transported at −70°C until analysis at Statens 
Serum Institut in Denmark, previously described in 
detail.24 Cytokine concentrations of interleukin (IL)-1β, 
IL-5, IL-6, IL-10, IL-17, interferon (IFN)-γ and tumour 
necrosis factor (TNF)-α in the resulting supernatants 
were analysed by an immunobead- based multiplexed 
assay based on flowmetric Luminex xMAP technology.
Statistical methods
We tested determinants of 2- month BCG skin reactions 
and reaction sizes to calculate risk ratios (RRs) using 
binomial regression. The BCG reaction size was calcu-
lated as the measured height plus width divided by two. 
Tertiles of reaction sizes were computed using the Stata 
xtile command. Due to aggregation of reaction sizes, the 
approximated tertiles do not represent exactly 33% of 
the total.
The 2–12 months mortality risk by BCG reaction 
status at 2 months of age was assessed in crude and 
adjusted Cox proportional hazards models providing 
mortality rate ratios (MRRs) with age as the underlying 
time variable; age was thus inherently controlled for in 
all analyses. We computed cumulative mortality curves 
using the Kaplan- Meier estimate based on the date of 
the BCG reaction assessment and the date of death or 
censoring. We present crude MRRs stratified by RCT 
and adjusted MRRs (aMRRs) stratified by RCT and 
adjusted for maternal MUAC, year and the assistant that 
assessed the reaction at the 2- month home- visit, anal-
ysed by reaction status (yes/no) at 2 months of age and 
reaction size tertile (small, medium or large). Person- 
years- at- risk (Pyrs) were calculated from the date of the 
2- month reaction assessment and infants contributed 
risk- time until they died, migrated or reached 12 months 
of age, whichever came first. Tests of proportionality of 
hazards were computed using Schoenfeld’s residuals. 
We conducted a supplementary analysis evaluating cause 
of death data collected at the HNSM paediatric ward, 
at home- visits and from standardised verbal autopsies 
using the WHO/INDEPTH questionnaire.25 The verbal 
autopsies were reviewed by local physicians who assigned 
the cause of death and were blinded to the infant’s BCG 
reaction status. The cause of death data was divided in 
infectious and non- infectious causes and analysed in Cox 
models providing aMRRs by 2- month reaction status and 
reaction size. We conducted a sensitivity analysis to test 
Figure 1 Measurement of an infant’s Bacille Calmette- 
Guérin skin reaction at the vaccine injection site in the left 
deltoid region during a home- visit within the BCGSTRAIN 
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whether assessor differences in 2- month BCG reaction 
assessments affected outcomes (online supplemental 
material). To analyse cytokine responses at 4 weeks of age 
among infants that were bled in RCT III, we compared 
log- transformed stimulated cytokine responses by 4- week 
reaction status (yes/no) and 4- week reaction size. Cyto-
kine values that were either over or under the detection 
limit of the assay were imputed using multiple imputation 
(n=20) for censored interval variables when less than 50% 
of values were censored, as described by Uh et al.26 When 
more than 50% of cytokine values were over the detec-
tion limit, values were dichotomised as detected or over- 
detection- limit. We assessed the data by linear regression 
or Poisson regression with robust variances adjusted for 
the non- stimulated response providing geometric mean 
ratios (GMRs) and prevalence ratios (PRs), respectively. 
All analyses were conducted overall and by sex using 
StataIC V.16 (Stata Corp) and all estimates are reported 
with 95% CIs.
RESULTS
The five RCTs included 21 957 infants, 12 465 of whom 
(RCT I: 104; II: 2320; III: 4158; IV: 3354; V 2529) were 
eligible for home- visits (figure 2). Of these, 9180 were 
randomised to receive early- BCG and 8103 of those 
were BCG- vaccinated during the first week of life. By 2 
months of age, 198 infants had died and 1867 were not 
found at home (figure 2). Four families refused our 
subsequent 6- month visit and were excluded from the 
analysis. In summary, a total of 6034 infants who had 
received BCG within 1 week of birth were found at home 
at the 2- month visit and 99.6% (6012/6034) of these had 
their BCG skin reaction evaluated. The median age at 
BCG vaccination was 1 day (online supplementary table 
1); 76% (4551/6012) were vaccinated within the first 2 
days of life. The 2- month BCG reaction prevalence was 
97% (5804/6012); 37% (2213/6012) of the infants had 
a small reaction (median size 3.5 mm, IQR 3.0–4.0), 
28% (1710/6012) had a medium reaction (5.0 mm, IQR 
4.5–5.0) and 31% (1881/6012) had a large reaction (6.0 
mm, IQR 5.5–7.0) (table 2).
Pustules (open lesions) represented 48% (2897/6012) 
of reactions with a median reaction size of 5.0 mm (4.0–
6.0), 7.5% (451/6012) were papules with a median size of 
4.5 mm (3.5–5.5) and 41% (2456/6012) were scars with 
a median size 4.0 mm (3.5–5.0). The median 2- month 
MUAC was 122 mm among non- reactors and 124 mm 
for reactors (p<0.001). Among reactors, the median 

















ealth: first published as 10.1136/bm






6 Schaltz- Buchholzer F, et al. BMJ Global Health 2020;5:e002993. doi:10.1136/bmjgh-2020-002993
BMJ Global Health
2- month MUAC was 122 mm for small- reactors, 124 mm 
for medium- reactors (p<0.001) and 128 mm for large- 
reactors (p<0.001).
Mortality risk
We registered 119 deaths between the 2- month visit 
and 12 months of age; mortality declined from 3.5% 
(77/2291) during the low- weight RCTs I–III to 0.8% 
(15/1962) in RCT V, which included both low- weight 
and normal- weight children (table 2). The all- cause 2–12 
month mortality across the trials was 4.8% (10/208) for 
non- reactors and 1.9% (109/5804) for reactors (table 3), 
the corresponding crude reactor/non- reactor MRR 
stratified by RCT being 0.48 (0.25–0.93) (table 4) and 
the aMRR 0.49 (0.26–0.95) (figure 3).
By sex, the reactor/non- reactor aMRR was 0.42 (0.15–
1.18) for male infants and 0.54 (0.23–1.26) for female 
infants (p for same effect=0.70) (online supplemental 
table 2).
By reaction size, the 2–12 months mortality risk was 
2.9% (64/2213) for infants with small reactions, 1.8% 
(30/1710) for medium reactions and 0.8% (15/1881) 
for large reactions (table 3). The large/small reaction 
aMRR was 0.35 (0.20–0.63) (figure 4). The associa-
tion between reaction size and mortality was consistent 
Table 2 Distribution of BCG skin reactions at the 2- month follow- up visit, median reaction size and all- cause mortality 

















of BCG skin 
reaction
Mortality between 
2 and 12 months 
% (n/N)
I–III 5 (112/2191) 95 (2079/2191) 45 (978/2191) 25 (552/2191) 25 (549/2191) 4.5 (3.5–5.5) 3.5 (77/2191)
IV 2 (41/1859) 98 (1818/1859) 32 (602/1859) 30 (565/1859) 35 (651/1859) 5.0 (4.0–5.5) 1.5 (27/1859)
V 3 (55/1962) 97 (1907/1962) 32 (633/1962) 30 (593/1962) 35 (681/1962) 5.0 (4.0–5.5) 0.8 (15/1962)
RCTs I–V 
combined
3 (208/6012) 97 (5804/6012) 37 (2213/6012) 28 (1710/6012) 31 (1881/6012) 4.5 (4.0–5.5) 2.0 (119/6012)
*Height plus width divided by two among infants with a reaction, in millimetres. The median size of small reactions was 3.5 mm (IQR 3.0 mm–4.0 
mm), for medium reactions it was 5.0 mm (4.5 mm–5.0 mm) and for large reactions it was 6.0 mm (5.5 mm–7.0 mm).
BCG, Bacille Calmette- Guérin; RCT, randomised controlled trial.
Table 3 Mortality risk between 2 and 12 months by 2- month BCG reaction status, reaction size and strain of BCG
RCT (years with 
inclusions)












  RCTs I–III (2002–2013)
BCG- Denmark 3.9 (38/978) 3.3 (18/552) 2.4 (13/549) 3.3 (69/2079) 7.1 (8/112) 3.5 (77/2191)
  RCT IV (2013–2017)
BCG- Denmark (2013–
2016)
2.6 (13/500) 2.0 (9/458) 0.0 (0/509) 1.5 (22/1467) 0.0 (0/30) 1.5 (22/1497)
BCG- Japan (2016–2017) 3.9 (4/102) 1.0 (1/107) 0.0 (0/142) 1.4 (5/351) 0.0 (0/11) 1.4 (5/362)
  RCT V phase I* (2014–
2016)
BCG- Denmark 1.6 (2/126) 0.6 (1/168) 0.4 (1/237) 0.8 (4/531) 0.0 (0/3) 0.8 (4/534)
BCG- Russia 0.8 (2/240) 0.0 (0/163) 0.0 (0/85) 0.4 (2/488) 4.6 (1/22) 0.6 (3/510)
  RCT V phase II* (2016–
2017)
BCG- Japan 1.0 (1/103) 0.0 (0/128) 0.4 (1/227) 0.4 (2/458) 8.3 (1/12) 0.6 (3/470)
BCG- Russia 2.4 (4/164) 0.8 (1/134) 0.0 (0/132) 1.2 (5/430) 0.0 (0/18) 1.1 (5/448)
  Total (2002–2017)
BCG- Denmark (RCTs I–V) 3.3 (53/1604) 2.4 (28/1178) 1.1 (14/1295) 2.3 (95/4077) 5.5 (8/145) 2.4 (103/4222)
BCG- Japan (RCTs IV–V) 2.4 (5/205) 0.4 (1/225) 0.3 (1/369) 0.9 (7/809) 4.4 (1/23) 1.0 (8/832)
BCG- Russia (RCT V) 1.5 (6/404) 0.3 (1/297) 0.0 (0/217) 0.8 (7/918) 2.5 (1/40) 0.8 (8/958)
  RCTs I–V, all strains 2.9 (64/2213) 1.8 (30/1710) 0.8 (15/1881) 1.9 (109/5804) 4.8 (10/208) 2.0 (119/6012)
RCT IV and RCT V recruited neonates up to September and October 2017, respectively, and follow- up procedures for the last recruited infants were 
completed one year later.
*RCT V featured two phases: one randomising infants to BCG- Denmark versus BCG- Russia (phase I) and one randomising infants to BCG- Japan 
versus BCG- Russia (phase II).
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Table 4 Mortality risk between 2 and 12 months by 2- month BCG reaction status and size
BCG skin reaction
2–12 month mortality rate
per 100 Pyrs (deaths/Pyrs) (N) Crude* MRR (95% CI)
Adjusted† MRR (95% 
CI)
Mortality risk by BCG reaction status
No reaction 6.3 (10/159) (208) Ref. Ref.
Has reaction 2.4 (109/4504) (5804) 0.48 (0.25 to 0.93) 0.49 (0.26 to 0.95)
Mortality risk by BCG reaction size
Small reaction 3.8 (64/1704) (2213) Ref. Ref.
Medium reaction 2.3 (30/1333) (1710) 0.68 (0.44 to 1.05) 0.69 (0.44 to 1.07)
Large reaction 1.0 (15/1466) (1881) 0.33 (0.19 to 0.58) 0.35 (0.20 to 0.63)
BCG- Denmark (RCTs I–V)
Mortality risk by BCG reaction size
Small reaction 4.3 (53/1229) (1604) Ref. Ref.
Medium reaction 3.1 (28/912) (1178) 0.80 (0.50 to 1.26) 0.82 (0.51 to 1.31)
Large reaction 1.4 (14/1014) (1295) 0.39 (0.22 to 0.71) 0.43 (0.23 to 0.78)
BCG- Japan (RCTs IV–V)
Mortality risk by BCG reaction size
Small reaction 3.1 (5/159) (205) Ref. Ref.
Medium reaction 0.5 (1/184) (235) 0.18 (0.02 to 1.55) 0.17 (0.02 to 1.47)
Large reaction 0.4 (1/283) (369) 0.12 (0.01 to 1.03) 0.11 (0.01 to 0.96)
BCG- Russia (RCT V)
Mortality risk by BCG reaction size
Small reaction 1.9 (6/316) (404) Ref. Ref.
Medium reaction 0.4 (1/238) (297) 0.22 (0.03 to 1.86) 0.19 (0.02 to 1.59)
Large reaction 0.0 (0/169) (217) – –
*Cox proportional hazards survival analysis (unadjusted, stratified by RCT), comparing mortality risk by reaction status (yes/no) and by BCG reaction size.
†Cox proportional hazards survival analysis by BCG reaction status (has reaction versus no reaction, small versus medium and small versus large reaction 
size) adjusted for maternal MUAC, year and 2- month reaction assessor, stratified by study, providing the aMRR estimate.
BCG, Bacille Calmette- Guérin; MRR, mortality rate ratio; Pyrs, person- years.
Figure 3 Kaplan- Meier curve of cumulative deaths up to 
1 year of age among infants with a Bacille Calmette- Guérin 
reaction versus no reaction. The statistical analysis is a 
reaction/no reaction Cox proportional hazards regression 
model with non- reactors as baseline, adjusted for maternal 
mid upper- arm circumference, year and 2- month reaction 
assessor, stratified by study, providing the adjusted mortality 
rate ratio (aMRR) estimate.
Figure 4 Kaplan- Meier curve of cumulative deaths up to 
1 year of age by Bacille Calmette- Guérin reaction size. All 
statistical analyses were conducted using Cox proportional 
hazards regression models with infants with small 
reactions as baseline, adjusted for maternal mid upper- arm 
circumference, year and 2- month reaction assessor, stratified 
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between BCG strains (table 4) and there was a consistent 
trend of decreasing mortality with increasing reaction 
size (p for trend <0.001, figure 5). There were no signifi-
cant differences between the sexes (online supplemental 
table 2). The mortality effects were consistent across the 
RCTs, with the exception that RCT IV had no deaths in 
the non- reactor group (online supplemental table 3).
Most deaths were caused by infection, 76% (87/114), 
and the reactor/non- reactor aMRR for infectious condi-
tions was 0.53 (0.24–1.17) (online supplemental table 
4). By reaction size, the infection aMRR for large versus 
small reactions was 0.32 (0.16–0.65). Our surveillance 
registered one death from TB in the cohort (online 
supplemental table 4).
There were no differences in reaction rates between 
ethnic groups, by maternal BCG scar status, by birth 
weight group (low weight vs normal weight) or by 
neonatal vitamin A supplementation status (table 5). 
The median maternal age was 26 years for reactors versus 
23 years for non- reactors (p=0.001) and the median 
maternal MUAC was 260 mm for reactors and 250 mm 
for non- reactors (p<0.01) (table 5). Due to the time trend 
of declining mortality across the RCTs and the possibility 
of differences in reaction assessments by the 2- month 
reaction assessor, the aMRRs presented were stratified by 
RCT and adjusted for maternal MUAC, year and 2- month 
reaction assessor. Our analyses were robust to adjustment 
for Caesarean section, maternal age and infant MUAC by 
2 months of age.
Place of inclusion, vaccinator and size of the post-vaccination 
weal
The RR for no- reaction was 2.43 (1.50–3.92) for inclusion 
at health centres versus HNSM (RCTs I–III, table 5). In 
RCTs III–V, the RR for no- reaction was 1.83 (1.25–2.67) 
for vaccinator 1 versus vaccinator 2. The mean size of 
the post- vaccination weal (measured only in RCT V) was 
4.3 mm for vaccinator 1 and 4.5 mm for vaccinator 2 
(p<0.001). The RR for no- reaction was 3.01 (1.44–6.29) 
for medium (≥4 mm, <5 mm) versus large (≥5 mm) post- 
vaccination weal size and 5.91 (2.62–13.3) for small (<4 
mm) versus large weal (table 6). There tended to be 
more medium and large- sized reactions and fewer small 
reactions associated with large weals (table 6).
BCG strain (RCT V)
For BCG- Denmark, 1% (3/534) of infants did not develop a 
reaction versus 4% (22/510) for BCG- Russia. Hence, the RR 
for no- reaction was 7.68 (2.31–25.5) for BCG- Russia versus 
BCG- Denmark (table 6). Large reactions represented 44% 
(237/534) of reactions for BCG- Denmark and 17% (85/510) 
for BCG- Russia, the RR for large reaction being 0.38 (0.30–
0.47) for BCG- Russia versus BCG- Denmark (table 6).
In phase II, 3% (12/470) of infants vaccinated with BCG- 
Japan did not develop a reaction versus 4% (18/448) for 
BCG- Russia, the RR for no- reaction being 1.57 (0.77–3.23) 
for BCG- Russia versus BCG- Japan. Large reactions repre-
sented 48% (227/470) of reactions for BCG- Japan and 29% 
Figure 5 Mortality risk by BCG reaction size in millimetres. ***P for trend <0.001 (logistic regression). 95% CIs (dotted lines) 
were calculated by logistic regression. Reaction sizes were calculated as the height plus the width of the reaction, divided by 
two. Reaction sizes displayed in this figure were rounded upwards: for example, a reaction size of 3.5 mm (width 4.0 mm and 
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(132/448) for BCG- Russia, the RR for large reaction being 
0.61 (0.51–0.72) for BCG- Russia versus BCG- Japan (table 6).
Evaluation of the correlation between cytokine responses and 
skin reaction by 4 weeks
In RCT III, a subgroup of 224 BCG- vaccinated infants 
had their BCG skin reaction assessed at a 4- week home- 
visit where a blood sample was obtained for immunolog-
ical assessment. The 4- week BCG reaction prevalence was 
92% (205/224) and having a 4- week BCG reaction was 
associated with a higher monocyte cell count, 1760/μL 
(1340–2330) for reactors versus 1240/μL (950–1830) 
for non- reactors (p=0.02). The neutrophil cell count 
was 2070/μL (1450–3010) for reactors versus 1850/μL 
(790–2610) for non- reactors (p=0.19). BCG reactors 
had higher responses to stimulation with PPD, especially 
IFN-γ (GMR=4.62 (1.70–12.4)), when compared with 
non- reactors (online supplemental figure 1A, table 5). 
A comparable pattern was seen after stimulation with 
heterologous TLR agonists and the pattern was strongest 
for the TLR-8 agonist CL075 (IFN-γ: GMR=2.20 (1.05–
4.62)), whereas both unstimulated and PMA- stimulated 
responses were generally higher among non- reactors 
Table 5 Determinants for having a BCG reaction at 2 months of age
Determinant Specification No reaction % (n/N)
Risk ratio for presenting 
no reaction*
(95% CI) or p value
Maternal BCG scar status (RCTs IV–V)† Mother has scar 2 (39/1586) Ref.
Mother has no scar 3 (26/958) 1.09 (0.67 to 1.78)
Maternal ethnicity (% of cohort) (RCTs 
I–V)
Balanta (15%) 3 (24/784) 1.60 (0.75 to 3.42)
Fula (20%) 3 (32/1039) 1.61 (0.78 to 3.35)
Mancanha (9%) 2 (9/471) Ref.
Mandinga (10%) 3 (15/515) 1.52 (0.67 to 3.45)
Manjaco (10%) 4 (18/517) 1.82 (0.83 to 4.02)
Pepel (17%) 4 (38/1006) 1.64 (0.78 to 3.45)
Other (19%) 3 (28/892) 1.98 (0.96 to 4.05)
Missing (13%) 6 (44/744) 2.92 (1.44 to 5.93)
Median maternal age in years (IQR) 
(RCTs I–III)
24 (19–28) (reactors) versus 23 
(19–29) (non- reactors)
NA p=0.66‡
Median maternal age in years (IQR) 
(RCTs IV–V)
27 (22–31) (reactors) versus 24 
(20–28) (non- reactors)
NA p=0.002‡
Median maternal age in years (IQR) 
(RCTs I–V)
26 (21–30) (reactors) versus 23 
(20–28) (non- reactors)
NA p=0.001‡
Median maternal MUAC (IQR) (RCTs 
I–III)
244 (226–260) (reactors) versus 
238 (226–256) (non- reactors)
NA p=0.84‡
Median maternal MUAC (IQR) (RCTs 
IV–V)
270 (250–298) (reactors) versus 
267 (249–294) (non- reactors)
NA p=0.49‡
Median maternal MUAC (IQR) (RCTs 
I–V)
260 (238–286) (reactors) versus 
250 (232–280) (non- reactors)
NA p<0.01‡
Place of inclusion (RCTs I–III)§ HDSS health centre 10 (21/213) 2.43 (1.50 to 3.92)
HNSM 5 (91/1978) Ref.
Weight group at inclusion (RCTs IV–V)¶ Normal weight (≥2.5 kg) 2 (75/3115) Ref.
Low weight (<2.5 kg) 3 (21/706) 1.33 (0.82 to 2.18)
Received neonatal vitamin A (RCT III)** Yes 7 (22/307) 1.38 (0.73 to 2.61)
No 5 (15/289) Ref.
Vaccinator
(RCTs III–V)
1 3 (106/3090) 1.83 (1.25 to 2.67)
2 2 (35/1877) Ref.
*Binomial regression, adjusted for RCT.
†Within a subgroup of 2544 infants included in RCTs IV–V, maternal BCG reaction assessments were performed at inclusion.
‡Kruskal- Wallis χ2 test with ties.
§Analysis comparing RCT I–III neonates since all infants in RCT IV–V were included at HNSM. At HNSM, vaccinator 1 and 2 performed all 
vaccinations while vaccinations at the HDSS health centres were performed by Bandim Health Project assistants that less frequently performed 
BCG vaccinations.
¶Analysis within studies IV–V which recruited both normal birth weight and low birth weight infants.
**RCT II was designed as a 2- by-2 factorial RCT with a subgroup of neonates randomised to receive either 25 000 International Units of NVAS or 
placebo, as well as either early- BCG or no- BCG.
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(PMA: IFN-γ: GMR=0.80 (0.75–0.87); unstimulated: 
IL-1β: GMR=0.40 (0.17–0.95), IL-6: GMR=0.33 (0.14–
0.79), TNF-α: GMR=0.51 (0.30–0.87), IL-17: GMR=0.44 
(0.20–0.95) and IL-10: GMR=0.45 (0.21–0.96)). Among 
all stimulus- cytokine combinations, a larger reaction 
was generally associated with higher cytokine responses 
(online supplemental figure 1B,C).
DISCUSSION
Having an early BCG reaction by 2 months of age was asso-
ciated with a substantial reduction in 2–12 months mortality. 
The larger the reaction, the more pronounced was the bene-
ficial effect on survival. This association was consistent across 
five RCTs and three BCG strains and protection was mainly 
against deaths caused by infectious diseases.
The main determinants for developing a BCG reaction 
were related to the quality of the BCG vaccination and the 
BCG strain used; BCG- Denmark and BCG- Japan were associ-
ated with higher reaction rates and larger reaction sizes than 
BCG- Russia.
By 4 weeks of age, both specific and heterologous cytokine 
responses were more pronounced among BCG reactors, and 
even more so in those with large 4- week reactions.
Strengths and weaknesses
Previous observational studies have examined infants vacci-
nated mainly during the first months of life rather than in 
the first week, and the BCG reaction assessments have mostly 
taken place later in infancy, focusing on the formation of the 
final BCG scar. Since mortality is higher earlier in life and 
BCG- at- birth is the recommended policy, and because there 
is less pre- vaccination exposure to environmental mycobac-
teria for those vaccinated at birth, it is important to evaluate 
the effects of BCG provided as close to birth as possible and 
the associated BCG skin reactions.
While birth weight was not a determinant for developing a 
BCG reaction, reactors had better 2- month anthropometric 
indices than non- reactors. Among reactors, larger reaction 
size was associated with higher 2- month MUAC indicating 
that infants with larger reaction sizes were or had become 
healthier. We considered the MUAC a mediator of the 
overall health effect of adequate BCG vaccination and our 
analyses were robust to adjustments for factors known to 
affect mortality.
Differences in classification of BCG reactions between 
different reaction assessors could have affected our 
results, but our analyses were robust to adjustment for 
the reaction assessor. Our analyses were stratified by RCT 
and revealed a consistent pattern of reduced mortality 
associated with both having a reaction and the reaction 
size across the trials.
The relative effect of having a large reaction was 
greatest in the two most recent trials, despite a lower 
overall mortality, a higher BCG reaction prevalence and 
more large reactions than in RCTs I–III. This is important 
because it indicates that BCG reaction sizes are important 
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relatively low and vaccination quality is high. The trend 
of reduced mortality associated with having an early BCG 
reaction and the reaction size, which was consistent across 
the five trials spanning 17 years, was robust to adjustment 
for RCT and calendar year, making confounding by 
chronology unlikely.
We only had cytokine data by 4 weeks of age, and could 
thus only conclude that cytokine production by 4 weeks 
of age correlated with BCG reaction characteristics at 4 
weeks of age, providing only circumstantial evidence for 
BCG reactions being correlated with increased cytokine 
responses to PPD and heterologous stimuli by 2 months 
of age.
Our surveillance detected only one death due to TB 
and it is thus unlikely that specific protection against TB 
played a substantial role in the observed effects.
Interpretation
All available studies have reported a beneficial effect on 
all- cause mortality of developing a BCG scar after BCG 
vaccination, but there is a remarkable variation in the 
BCG scar prevalence ranging from 52% (18 535/35 
416) in a large observational study from rural Bissau11 
to the 97% (5804/6012) reaction prevalence in the 
present study. This indicates that the beneficial effects 
on mortality are not merely caused by healthier infants 
responding better to vaccination. Rather, as corroborated 
in the present study, it is the quality of vaccination (post- 
vaccination weal size, vaccination by trained personnel at 
a major hospital) and the BCG strain administered that 
are the main determinants for developing a reaction and 
the size of the reaction.
We found that BCG- Russia is associated with fewer and 
smaller BCG reactions by 2 months of age. Previous BHP 
studies and a study from Uganda have indicated that BCG- 
Russia produces fewer BCG scars.14 27–29 In a small RCT 
from Australia, BCG- Russia was associated with smaller 
skin reactions and less favourable immune responses17 
and BCG- Russia was furthermore associated with fewer 
tuberculin skin test responses in the randomised compar-
isons with both BCG- Japan and BCG- Denmark in RCT 
V.15 A large retrospective study from Kazakhstan reported 
that while BCG- Russia provided some protection against 
TB when compared with unvaccinated infants, BCG- 
Japan was associated with the highest protective efficacy 
against TB.30 The available data thus indicates that BCG- 
Denmark and BCG- Japan are more immunogenic than 
BCG- Russia. These findings might help explain why two 
recent RCTs providing BCG- Russia versus no BCG did not 
show an effect of BCG- Russia on the all- cause neonatal 
mortality.31 Other major BCG strains such as BCG- 
Bulgaria (genetically identical to BCG- Russia) and BCG- 
GreenSignal (genetically identical to BCG- Denmark) 
remain to be evaluated.
BCG is a strong immunostimulant5 and a study in mice 
has underlined the importance of vaccination technique, 
indicating that access of BCG to the bone marrow changes 
the transcriptional landscape of haematopoietic stem 
cells and multipotent progenitors, inducing immune 
training.32 Similarly, a recent analysis in humans indi-
cated that BCG induces transcriptomic myeloid priming 
of the haematopoietic stem and progenitor cell compart-
ment, which induces transcription factors connected to 
myeloid cell function. This resulted in elevated gran-
ulocyte numbers and induced lasting innate immune 
system memory.33 Such biological effects depending on 
BCG’s access to the bone marrow are likely influenced 
by the absolute number of viable mycobacteria depos-
ited within the host, which are determined by the BCG 
strain, injection technique and the dose injected (post- 
vaccination weal size). A recent laboratory study has elab-
orated the differences between BCG strains in terms of 
the content of colony- forming units and the percentage 
of live versus dead bacteria.34 The marked in vitro differ-
ences in viability between strains reported, which favour 
BCG- Denmark and BCG- Japan over BCG- Russia, provide 
a plausible biological explanation to our epidemiolog-
ical findings. Large BCG reactions thus likely represent 
a well- trained innate immune system. We found that 
having an early reaction is accompanied with more 
innate immune training in vitro, which have been associ-
ated with reduced viral and parasitic load after challenge 
in other studies.35 36 Intriguingly, early reactions were at 
the same time associated with less reactivity in the unstim-
ulated samples, that is, in steady state, possibly reflecting 
less infection/inflammation in infants with an early BCG 
reaction.
Policy implications
It is paramount to introduce measures that eliminate 
known logistic barriers to vaccination37 38 so that BCG 
can be provided shortly after birth to produce high BCG 
reaction rates. We demonstrate that feasible targets are 
2- month BCG reaction rates of ≥96% for BCG- Russia and 
≥97% for BCG- Japan and BCG- Denmark, with 30% of 
early reactions being ≥6.0 mm. BCG reactions should be 
surveyed by 2 months of age to detect immunisation fail-
ures, weak BCG strains and batch- to- batch variations that 
are known to occur within strains.39 Observational studies 
from rural Guinea- Bissau has reported that the 1- month 
BCG vaccination coverage was just 38% and among 35 
416 BCG- vaccinated children under 5 years of age, the 
BCG scar prevalence was just 52%.11 38 Similarly, a study 
from 2009 reported that the neonatal BCG vaccination 
coverage in sub- Saharan Africa is below 50%, despite 
the WHO recommendation of BCG- at- birth.40 Updated 
data on vaccination coverage and early BCG reaction 
prevalence is needed, however, to fully assess the current 
impact of early BCG vaccination and the potential impact 
of improved vaccination policies. There seems to be a 
vast potential for reducing early- life mortality by ensuring 
adequate training of vaccinators, a high neonatal BCG 
coverage and surveillance of subsequent BCG reactions. 
Addressing immunisation failures by providing revacci-
nation to non- reactors might also be an untapped low- 
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protection and reduce all- cause mortality. This could be 
performed in conjunction with the health centre contact 
occurring at 14 weeks of age, when the third dose of 
pentavalent vaccine is provided. As an added benefit, 
providing BCG at this time might remedy the previously 
reported detrimental NSEs on overall survival related to 
pentavalent vaccination.41 To enhance beneficial NSEs, 
the use of immunogenic BCG strains is to be encouraged.
CONCLUSION
Our analysis corroborated that developing a BCG reac-
tion is associated with a substantial survival benefit and 
extended these findings, by showing that having a skin 
reaction already by 2 months of age and the reaction 
size were associated with substantial additional benefits. 
Compared with BCG- Russia, BCG- Denmark and BCG- 
Japan induce more reactions that are also larger. This 
indicates a long- term association between adequate early 
vaccination with specific BCG strains, subsequent skin 
reaction kinetics, and survival.
Given the public health implications, it is urgent that 
data from other settings are examined to test whether 
our findings can be replicated. With little additional 
costs, an increased focus on timely BCG vaccination, 
immunogenic BCG strains and vaccination quality could 
save many infant lives globally, given that BCG is adminis-
tered to >120 million infants per year.
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